NUVALENT INC
NASDAQ: NUVL (Nuvalent, Inc.)
Kemas kini terakhir: 13 jam lalu123.43
0.07 (0.06%)
| Penutupan Terdahulu | 123.36 |
| Buka | 123.40 |
| Jumlah Dagangan | 3,945,950 |
| Purata Dagangan (3B) | 1,995,075 |
| Modal Pasaran | 9,766,798,336 |
| Harga / Buku (P/B) | 8.31 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| EPS Cair (TTM) | -4.42 |
| Nisbah Semasa (MRQ) | 14.48 |
| Aliran Tunai Operasi (OCF TTM) | -203.80 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -98.58 M |
| Pulangan Atas Aset (ROA TTM) | -22.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -35.69% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Nuvalent, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.50 |
|
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.85% |
| % Dimiliki oleh Institusi | 110.02% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Deerfield Management Company, L.P. | 31 Mar 2026 | 17,248,450 |
| Paradigm Biocapital Advisors Lp | 31 Mar 2026 | 5,324,433 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BOGLE GRANT C. | 123.39 | - | 3,444 | 424,955 |
| MEYERS MICHAEL L. | 123.39 | - | 3,444 | 424,955 |
| NOCI DARLENE | - | 123.25 | -20,000 | -2,465,000 |
| OLIGER CHRISTY J. | 123.39 | - | 3,444 | 424,955 |
| PORTER JAMES RICHARD | - | 88.49 | -30,000 | -2,654,700 |
| PROTOPAPAS ANNA | 123.39 | - | 3,444 | 424,955 |
| SQUARER RON | 123.39 | - | 3,444 | 424,955 |
| SRIVASTAVA SAPNA | 123.39 | - | 3,444 | 424,955 |
| WHEELER CAMERON | 123.39 | - | 3,444 | 424,955 |
| Jumlah Keseluruhan Kuantiti Bersih | -25,892 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,145,014 | |||
| Purata Pembelian Keseluruhan ($) | 123.39 | |||
| Purata Jualan Keseluruhan ($) | 105.87 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BOGLE GRANT C. | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,444 | 123.39 | 424,955 |
| MEYERS MICHAEL L. | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,444 | 123.39 | 424,955 |
| OLIGER CHRISTY J. | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,444 | 123.39 | 424,955 |
| PROTOPAPAS ANNA | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,444 | 123.39 | 424,955 |
| SQUARER RON | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,444 | 123.39 | 424,955 |
| SRIVASTAVA SAPNA | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,444 | 123.39 | 424,955 |
| WHEELER CAMERON | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,444 | 123.39 | 424,955 |
| NOCI DARLENE | Pegawai | 09 Jun 2026 | Jual automatik (-) | 20,000 | 123.25 | 2,465,000 |
| NOCI DARLENE | Pegawai | 09 Jun 2026 | Pelaksanaan pilihan | 20,000 | - | - |
| PORTER JAMES RICHARD | Pegawai | 08 Jun 2026 | Jual automatik (-) | 30,000 | 88.49 | 2,654,700 |
| PORTER JAMES RICHARD | Pegawai | 08 Jun 2026 | Pelaksanaan pilihan | 30,000 | - | - |
| Papar semua | ||||||
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |